Literature DB >> 29737401

Transplantation of adipose tissue-derived stem cells ameliorates autoimmune pathogenesis in MRL/lpr mice : Modulation of the balance between Th17 and Treg.

W Zhang1,2, Y-L Feng3, C-Y Pang1,2, F-A Lu1,2, Y-F Wang4,5.   

Abstract

BACKGROUND: Mesenchymal stem cells (MSCs) are multipotent cells characterized by immunomodulatory properties and are therefore considered a promising tool for the treatment of autoimmune diseases. In this study, we aimed to investigate whether transplantation of adipose tissue-derived stem cells (ADSCs) affects the autoimmune pathogenesis in MRL/lpr mice.
METHODS: Fifteen 12-week-old MRL/lpr mice were randomly divided into three groups: ADSC, cyclophosphamide (CTX), and control groups, with five mice in each group. ADSC and control groups were injected with 1 × 106 ADSCs or PBS, respectively, via the tail vein, once a week for 8 weeks. The CTX group was injected with CTX at a dose of 15 mg/kg body weight, once a week for 2 weeks, and this was repeated after 2 weeks rest. Proteinuria, anti-double-stranded DNA (anti-dsDNA) antibody, and serum creatinine levels were then measured. The populations of Th17 and Treg cells in the spleen were detected by flow cytometry. All statistical analyses were performed using least square difference.
RESULTS: Eight weeks after treatment, the 24 h proteinuria, anti-dsDNA antibody levels, and serum creatinine were decreased significantly with transplantation of mouse ADSCs. ADSCs markedly reduced the number of TH17 cells, increased Treg cells, and improved renal pathology.
CONCLUSION: Our results indicate that transplantation of ADSCs could significantly inhibit autoimmune progression in MRL/lpr mice and the efficacy of ADSCs was comparable to that of CTX.

Entities:  

Keywords:  Autoantibodies; Autoimmune diseases; Cyclophosphamide; Lupus nephritis; Systemic lupus erythematosus

Mesh:

Year:  2019        PMID: 29737401     DOI: 10.1007/s00393-018-0450-5

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  6 in total

Review 1.  Mesenchymal Stem Cell-Derived Extracellular Vesicles as Non-Coding RNA Therapeutic Vehicles in Autoimmune Diseases.

Authors:  Olga Martinez-Arroyo; Ana Ortega; Maria J Forner; Raquel Cortes
Journal:  Pharmaceutics       Date:  2022-03-29       Impact factor: 6.525

Review 2.  Extracellular Vesicles Released from Stem Cells as a New Therapeutic Strategy for Primary and Secondary Glomerulonephritis.

Authors:  Marco Quaglia; Guido Merlotti; Laura Fornara; Andrea Colombatto; Vincenzo Cantaluppi
Journal:  Int J Mol Sci       Date:  2022-05-20       Impact factor: 6.208

3.  Impact of Adipose-Derived Mesenchymal Stem Cells (ASCs) of Rheumatic Disease Patients on T Helper Cell Differentiation.

Authors:  Ewa Kuca-Warnawin; Magdalena Plebańczyk; Marzena Ciechomska; Marzena Olesińska; Piotr Szczęsny; Ewa Kontny
Journal:  Int J Mol Sci       Date:  2022-05-10       Impact factor: 6.208

Review 4.  Extracellular Vesicles as Nanotherapeutics for Parkinson's Disease.

Authors:  Loredana Leggio; Greta Paternò; Silvia Vivarelli; Francesca L'Episcopo; Cataldo Tirolo; Gabriele Raciti; Fabrizio Pappalardo; Carmela Giachino; Salvatore Caniglia; Maria Francesca Serapide; Bianca Marchetti; Nunzio Iraci
Journal:  Biomolecules       Date:  2020-09-16

5.  Adipose-derived stem cells postpone the progression of Sjögren's syndrome by upregulating the Hippo signaling pathway.

Authors:  Zizhan Li; Xinli Fan; Xiuying Xu; Qin Zhou; Guimiao Xing; Gangli Liu
Journal:  Exp Ther Med       Date:  2022-07-22       Impact factor: 2.751

6.  Adipose-derived mesenchymal stem cells alleviate TNBS-induced colitis in rats by influencing intestinal epithelial cell regeneration, Wnt signaling, and T cell immunity.

Authors:  Jian-Guo Gao; Mo-Sang Yu; Meng-Meng Zhang; Xue-Wei Gu; Yue Ren; Xin-Xin Zhou; Dong Chen; Tian-Lian Yan; You-Ming Li; Xi Jin
Journal:  World J Gastroenterol       Date:  2020-07-14       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.